|1.||Woerle, Hans-Juergen: 25 articles (11/2015 - 06/2010)|
|2.||Patel, Sanjay: 15 articles (11/2015 - 01/2012)|
|3.||Klein, Thomas: 15 articles (03/2015 - 01/2011)|
|4.||von Eynatten, Maximilian: 13 articles (11/2015 - 01/2012)|
|5.||Woerle, H-J: 11 articles (02/2015 - 01/2011)|
|6.||Hocher, Berthold: 8 articles (11/2015 - 01/2011)|
|7.||von Eynatten, M: 8 articles (02/2015 - 04/2012)|
|8.||Gong, Yan: 7 articles (11/2015 - 01/2013)|
|9.||Retlich, Silke: 7 articles (07/2015 - 12/2010)|
|10.||Graefe-Mody, Ulrike: 7 articles (07/2015 - 12/2010)|
|1.||Type 2 Diabetes Mellitus (MODY)
03/26/2011 - "In two double-blind, multicentre trials (n >350 evaluable patients/trial) in adult patients with inadequately controlled type 2 diabetes mellitus, oral linagliptin monotherapy (5 or 10 mg once daily) was significantly more effective than placebo in improving glycaemic control and several parameters of pancreatic function, with placebo-corrected adjusted mean changes in glycosylated haemoglobin (HbA(1c)) levels of -0.69% to -0.88% after 12 or 24 weeks. "
05/01/2015 - "The single-pill combination of linagliptin and empagliflozin, with their complementary mechanisms of action, is a promising treatment option for patients with type 2 diabetes mellitus. "
09/01/2013 - "To evaluate the long-term safety and efficacy of linagliptin as add-on therapy to one approved oral antidiabetic drug (OAD) in Japanese patients with type 2 diabetes mellitus and insufficient glycaemic control. "
02/01/2015 - "Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment - retrospective observation study of Japanese patients with type 2 diabetes mellitus."
11/01/2014 - "Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials."
|2.||Hypoglycemia (Reactive Hypoglycemia)
01/01/2010 - "Linagliptin is a new oral antidiabetic agent associated with minimal risk of hypoglycemia, which holds promise for treatment of type 2 diabetes."
12/01/2015 - "The once daily oral combination of linagliptin plus empagliflozin does not increase the risk of hypoglycemia and tolerability and discontinuation rates are similar to those with each as monotherapy. "
12/01/2015 - "Linagliptin, a DPP-4 inhibitor, reduces HbA1c, is weight neutral, has an excellent safety profile and a low risk of hypoglycemia. "
11/01/2015 - "Hypoglycemia was reported by one linagliptin patient and no placebo patients. "
06/01/2015 - "Incidence of investigator-defined hypoglycemia was similar between the two groups (linagliptin, 12.1%; placebo, 11.7%). "
04/01/2013 - "These findings provide evidence for the safety and tolerability of oral linagliptin at either 5 or 10 mg for up to 52 weeks for the treatment of Japanese patients with T2DM, without clinically relevant increase in the risk of hypoglycaemia or weight gain."
06/01/2015 - "Linagliptin provided clinically significant improvements in glycemic control without increased risk of hypoglycemia and without weight gain, representing a useful type 2 diabetes therapy option for the black/African American population."
01/01/2015 - "This review describes the overall safety and tolerability of linagliptin--a dipeptidyl peptidase-4 inhibitor that improves glycemic control without increasing risk for hypoglycemia and without weight gain. "
05/01/2013 - "Consistent with other members of its class, the benefits of linagliptin also include a low risk of hypoglycemia and weight gain. "
09/01/2012 - "The overall tolerability of linagliptin was similar to that of placebo, with a low risk for hypoglycemia and no significant weight gain. "
11/01/2013 - "Linagliptin administered in addition to stable RAAS inhibitors led to a significant reduction in albuminuria in patients with type 2 diabetes and renal dysfunction. "
10/08/2014 - "Recently it has been observed that type 4 dipeptidyl peptidase (DPP-4) inhibitor linagliptin is effective for treating type 2 diabetes and albuminuria. "
11/01/2015 - "Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial."
01/01/2014 - "Reduction of albuminuria with linagliptin on top of inhibitors of the renin-angiotensin-aldosterone system in both preclinical and post hoc clinical analysis serves as the foundation for ongoing clinical trials. "
11/01/2013 - "The ability of linagliptin to lower albuminuria on top of renin-angiotensin-aldosterone system (RAAS) inhibition in humans was analyzed by pooling data from four similarly designed, 24-week, randomized, double-blind, placebo-controlled, phase III trials. "
05/01/2014 - "The aim of this study was to determine whether linagliptin impacts stroke-induced neurogenesis. "
05/01/2014 - "We recently showed that the DPP-4 inhibitor linagliptin reduces brain damage after stroke in normal and type 2 diabetic (T2D) mice. "
05/01/2014 - "Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice."
01/01/2014 - "In addition to these characteristics, preclinical research on linagliptin has yielded several interesting findings such as improved wound healing, reduced hepatic fat content, decreased infarct size following myocardial infarction or intracranial stroke, and improved vascular function with decreased oxidative stress. "
05/01/2014 - "Stroke was induced by middle cerebral artery occlusion 4 weeks into the linagliptin treatment. "
|4.||Glucagon-Like Peptide 1 (GLP 1)